Causes and predictors of short, intermediate and long-term mortality in patients with coronary artery disease M. Zeitouni, N. Procopi, O. Barthélémy, Q.

Slides:

Advertisements

Similar presentations

Rethinking Lower Blood Pressure Goals for Diabetic Patients with Coronary Artery Disease – Findings from the INternational VErapamil SR – Trandolapril.

Advertisements

Nicolas DANCHIN, HEGP, Paris. Collaborations Subventions de recherche : Pfizer, Servier, The MedCo Honoraires pour conférences et/ou consultance: Astra-Zeneca,

Decline in the Use of Drug-Eluting Stents for Patients With NSTEMI Undergoing PCI: Results From the CRUSADE and ACTION Registries Matthew T. Roe, Christopher.

ARCTIC investigators COI D ISCLOSURE FOR D R. M ONTALESCOT : Research Grants to the Institution or Consulting/Lecture Fees from Abbott Vascular, Astra-Zeneca,

PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,

on behalf of the INVEST Investigators

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

COI Disclosure for Dr. Montalescot: Research Grants to the Institution or Consulting/Lecture Fees from Abbott Vascular, Astra-Zeneca, Bayer, Biotronik,

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.

AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.

Safety and Efficacy of Switching from Either UFH or Enoxaparin Plus a GP IIb/IIIa Inhibitor to Bivalirudin Monotherapy in Patients with Non-ST Elevation.

Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Procedural Outcomes of Chronic Total Occlusion Percutaneous.

Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events Andres J. Yarur, MD, Amar R. Deshpande, MD, David M. Pechman,

The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Transcatheter Aortic Valve Replacement Andres M. Pineda MD, J. Kevin.

Associate Professor, Honorary Consultant Cardiologist

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

On behalf of the TRILOGY ACS Investigators

Single IMA {Single Arterial}

ST-Elevation Myocardial Infarction: Findings from the ATLANTIC Trial

Should we care about post-procedural troponin in elective coronary stenting ? Michel Zeitouni, Johanne Silvain*, Mathieu Kerneis, Olivier Barthelemy,

Institut de Cardiologie - Pitié-Salpêtrière Hospital

When should we start a P2Y12 inhibitor in patients with an acute coronary syndrome? G. Montalescot Dr. Montalescot reports research Grants to the Institution.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Artificial Neural Network based model enhances risk.

Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus

Impact of Percutaneous Coronary Angioplasty and Extra-Corporal Life Support on Survival of Patients with Out of Hospital Cardiac Arrest. Morgan Benais,

Clinical impact and predictors of complete ST-segment resolution after primary percutaneous coronary intervention: a subanalysis of the ATLANTIC Trial.

Washington Hospital Center, Division of Cardiology

Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,

Racial Differences in the Association between Clinical Measures and Self-Reported Health Status in Bypass Angioplasty Revascularization Investigation.

SYNTAX at 2 Years: This Interventionalist’s Perspective

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

The EUROMAX trial is supported by The Medicines Company

MACE Trial Rationale, Study Design, and Current Status

POISE-2 PeriOperative ISchemic Evaluation-2 Trial

On behalf of J. Belardi, M. Leon, L. Mauri,

Has acute myocardial infarction mortality hit rock bottom

The ANTARCTIC investigators

Kristin Newby and the EARLY-ACS investigators

with type 2 diabetes without heart failure?

Cardiovascular outcomes

Two-Year Extended Follow-up in Patients Receiving a Zotarolimus-eluting Stent in the E-Five Registry Martin T. Rothman, Ian T. Meredith, Keyur Parikh,

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Recurrent Angina: New Tools for an Old Problem

European Heart Association Journal 2007 April

Giuseppe Biondi Zoccai, MD

3-Year Clinical Outcomes From the RESOLUTE US Study

Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in a Real-World Population: Three-Year Clinical Outcomes from.

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

on Behalf of the COGENT Investigators

Impact of Platelet Reactivity Following Clopidogrel Administration

STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.

Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.

Implications of Preoperative Thienopyridine Use

For the ACTION study group

Impact of Diabetes Mellitus on Long-term Outcomes in the

DEScover: One-Year Clinical Results

Ahmed A. Khattab, MD For the German Cypher Registry Investigators

Atlantic Cardiovascular Patient Outcomes Research Team

Glenn N. Levine et al. JACC 2011;58:e44-e122

Procedural Characteristics

Left Ventricular Thrombus Total LVT regression (n=99)

Clinical Case Gilles Montalescot

A. Procopi, N. Procopi, JP Collet, O. Barthelemy, P. Leprince, R

INNOVATIONS IN DIGITAL MEDICINE User experience for an acute cardiac care department G. Montalescot Institute of Cardiology, Pitié-Salpêtrière Hospital,

Presentation transcript:

Causes and predictors of short, intermediate and long-term mortality in patients with coronary artery disease M. Zeitouni, N. Procopi, O. Barthélémy, Q. Fischer, M. Kerneis, N. Hammoudi, E. Berman, R. Choussat, P. Guedeney, N. Braik, JP. Collet, J. Silvain, C. Le Feuvre, G. Montalescot, G. Helft Institute of Cardiology, Pitié-Salpêtrière hospital, Paris, France Table 1. Baseline characteristics Abstract Background: Little is known regarding long-term outcomes related to adverse cardiovascular events and non-cardiovascular events. Purpose: To describe causes and predictors of short-term, intermediate-term, and long-term mortality after PCI. Methods: Consecutive men and women admitted for PCI from 2008 to 2011 were prospectively included and followed-up in this cohort study. A pre-established and dedicated follow-up was performed in consultation and by calls to collect outcomes and the exact causes of death. Two independent reviewers adjudicated the events between cardiovascular or non-cardiovascular death. Last detailed cardiovascular and vital status were collected in January 2019. Results: A total of 3524 patients including 2720 men (77.2%) and 804 women (22.8%) were followed-up for a median time of 7.0 years (IQ1: 5.4 ; IQ3: 7.2). All-cause death occurred for 30.3% (n=1070) of patients in the cohort, in a median time of 2.5 years after PCI, with a rate of 5.3 deaths per 100 patient-years. Overall, patients were more likely to die from a cardiovascular cause than non-cardiovascular (17.7 % versus 12.6 %, log-rank <0.001) (figure 1). This trend was stronger within 30 days (4.7% vs. 0.3 %, p<0.0001) and the first year after PCI (3.1 % vs. 2.2 p =0.01), but became non-significant beyond one year (9.9% vs. 10.2%, P=0.67). Of note, cancer was the major cause of non-cardiovascular death (5.6%; 1 per 100 patient-years) (figure 3). The strongest risk factors for all-cause mortality along time were diabetes (adHR = 1.48 95CI% [1.29 – 1.71], p<0.001), active smoking (adHR = 1.37, 95CI% [1.16 – 1.62]) and chronic kidney disease (adHR = 1.97, 95CI% [2.55 – 3.45], p<0.001). Fig.2 Causes of cardiovascular death Study Population (N=3524) Age (years), median, [IQR] 65.4 [56.9 – 75.7] Family history of CAD 617 (17.5%) Dyslipidemia 1980 (56.2%) BMI (kg/m2), median, [IQR] 25.7 [23.4 – 28.6] Diabetes mellitus 1022 (29%) Hypertension 2125 (60.3%) Active smoking 979 (28.3%) Chronic kidney disease* 962 (27.3%) History of MI or CABG or PCI 1249 (35.4%) Clinical presentation MI 1876 (53.2%) Stable angina 729 (20.7%) Silent ischemia 613 (17.4%) Other 270 (7.7%) Angiographic characteristics Left main 200 (5.7%) Left anterior descending 2263 (34.2%) Left circumflex 1632 (46.3%) Right coronary artery 1935 (54.9%) Lesion on CABG 163 (4.6%) Number of vessels 1 vessel 1716 (48.7%) 2 vessels 1076 (30.5%) 3 vessels 732 (20.8%) Multivessel disease 1809 (51.3%) Fig.3 Causes of non-cardiovascular death Fig.1 Cumulative incidence of cardiovascular and non cardiovascular death Conclusion: In this prospective cohort study, cardiovascular death outer-passed non-cardiovascular death in patients treated with PCI in the short and intermediate-term but not beyond one year. Cancer accounted for one fifth of the overall mortality. Disclosures : MZ : FFC, Institut Servier, BMS/Pfizer ; MK : FFC, institut servier, NH : Philips, GE healthcare, Bayer, Laboratoires Servier, Novartis Pharma, Astra Zeneca, BMS, MSD, FFC, and ICAN JS : Amed, Amgen, Algorythm, Astra-Zeneca, Bayer, Daiichi-Sankyo, Eli Lilly, Fondation de France, Gilead Science, Iroko Cardio, Sanofi-Aventis and Saint-Jude Medical. JPC :AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eli-Lilly, Fédération Française de Cardiologie, Lead-Up, Medtronic, MSD, Sanofi-Aventis, WebMD. GM : Abbott, Amgen, Actelion, AstraZeneca, Bayer, Boehringer Ingelheim, Boston-Scientific, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Cardiovascular Research Foundation, Daiichi-Sankyo, Idorsia, Lilly, Europa, Elsevier, Fédération Française de Cardiologie, ICAN, Medtronic, Journal of the American College of Cardiology, Lead-Up, Menarini, MSD, Novo-Nordisk, Pfizer, Sanofi, Servier, The Mount Sinai School, TIMI Study Group, WebMD.